[go: up one dir, main page]

TR201907147T4 - Fgfr inhibitörünün aralıklı uygulanmasına yönelik anti-tümör ilaç. - Google Patents

Fgfr inhibitörünün aralıklı uygulanmasına yönelik anti-tümör ilaç. Download PDF

Info

Publication number
TR201907147T4
TR201907147T4 TR2019/07147T TR201907147T TR201907147T4 TR 201907147 T4 TR201907147 T4 TR 201907147T4 TR 2019/07147 T TR2019/07147 T TR 2019/07147T TR 201907147 T TR201907147 T TR 201907147T TR 201907147 T4 TR201907147 T4 TR 201907147T4
Authority
TR
Turkey
Prior art keywords
fgfr inhibitor
tumor drug
intermittent administration
present
salt
Prior art date
Application number
TR2019/07147T
Other languages
English (en)
Inventor
Ochiiwa Hiroaki
Hirai Hiroshi
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of TR201907147T4 publication Critical patent/TR201907147T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Mevcut buluş aracılığıyla çözülecek problem, FGFR inhibitörünün antitümör etkisi muhafaza edilirken yüksek kan fosfor seviyeleri gibi azaltılmış yan etkilere sahip olan güçlü ve yüksek derecede seçici yeni bir FGFR inhibitörü ve bir antitümör ajan sağlamaktır. Mevcut buluş, Formül (I) ile temsil edilen bir 3,5-disübstitüe benzen alkinil bileşiğini veya kullanılan bir tuzunu içeren bir antitümör ajanı sağlar böylece 3,5-disübstitüe benzen alkinil bileşiği veya bunun bir tuzu, haftada en az iki kere ve en az bir günlük bir dozlama aralığı olmak üzere bir uygulama programıyla uygulanır.
TR2019/07147T 2013-07-18 2014-07-17 Fgfr inhibitörünün aralıklı uygulanmasına yönelik anti-tümör ilaç. TR201907147T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013149963 2013-07-18

Publications (1)

Publication Number Publication Date
TR201907147T4 true TR201907147T4 (tr) 2019-06-21

Family

ID=52346281

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/07147T TR201907147T4 (tr) 2013-07-18 2014-07-17 Fgfr inhibitörünün aralıklı uygulanmasına yönelik anti-tümör ilaç.

Country Status (14)

Country Link
US (2) US20160193210A1 (tr)
EP (1) EP3023100B1 (tr)
JP (1) JP6084291B2 (tr)
KR (1) KR101974254B1 (tr)
AU (1) AU2014291161B2 (tr)
DK (1) DK3023100T3 (tr)
ES (1) ES2724929T3 (tr)
HU (1) HUE044273T2 (tr)
PL (1) PL3023100T3 (tr)
PT (1) PT3023100T (tr)
RU (1) RU2664118C2 (tr)
TR (1) TR201907147T4 (tr)
TW (1) TWI574691B (tr)
WO (1) WO2015008839A1 (tr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3023100T3 (da) 2013-07-18 2019-05-27 Taiho Pharmaceutical Co Ltd Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer
US10124003B2 (en) 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
CN105837575B (zh) * 2015-01-13 2019-01-15 四川大学 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途
ES2812785T3 (es) * 2015-03-31 2021-03-18 Taiho Pharmaceutical Co Ltd Cristal de compuesto de alquinilo de benceno 3,5-disustituido
KR20250007056A (ko) 2016-03-04 2025-01-13 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
CN107698593A (zh) 2016-08-09 2018-02-16 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
CN107840842A (zh) 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
HUE067430T2 (hu) 2018-03-19 2024-10-28 Taiho Pharmaceutical Co Ltd Nátrium-laurilszulfátot tartalmazó gyógyászati készítmény
KR102742083B1 (ko) 2018-11-09 2024-12-16 다이호야쿠힌고교 가부시키가이샤 디메톡시벤젠 화합물의 제조 방법
EP3882248A4 (en) 2018-11-09 2022-07-06 Taiho Pharmaceutical Co., Ltd. ANALOGS OF DIMETHOXYBENZENE COMPOUNDS, METHODS FOR THE ANALYSIS OF THE SAME COMPOUNDS AND STANDARD PRODUCTS OF THE SAME COMPOUNDS
EP3888643A4 (en) 2018-11-26 2022-08-24 Taiho Pharmaceutical Co., Ltd. Therapeutic and prophylactic method for tumor treatable with endocrine therapy by combined use of fibroblast growth factor receptor inhibitor with endocrine therapy
WO2020170355A1 (ja) * 2019-02-20 2020-08-27 大鵬薬品工業株式会社 Ｆｇｆｒ１変異腫瘍の治療方法
JP7805285B2 (ja) * 2020-04-10 2026-01-23 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物とｍｅｋ阻害剤とを用いた癌治療法
KR20230035031A (ko) 2020-06-05 2023-03-10 킨네이트 바이오파마 인크. 섬유아세포 성장 인자 수용체 키나아제의 억제제
AU2021285974A1 (en) * 2020-06-05 2023-01-19 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
TWI797711B (zh) * 2020-08-13 2023-04-01 大陸商上海和譽生物醫藥科技有限公司 一種fgfr及其突變抑制劑，其製備方法和應用
CN114805359B (zh) * 2021-01-28 2023-10-27 药雅科技(上海)有限公司 炔代杂环化合物fgfr抑制剂的制备方法和用途
CN115028634B (zh) * 2021-03-08 2023-11-28 药雅科技(上海)有限公司 一种炔代吡嗪并杂环类fgfr抑制剂及其制备方法和用途
CN115785103A (zh) * 2022-12-28 2023-03-14 北京康立生医药技术开发有限公司 一种治疗胆管癌药物福巴替尼的合成方法
CN120172981B (zh) * 2025-05-20 2025-07-25 南京工业大学 一类以fgfr2为靶点的小分子降解剂及其药物组合物和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007083A2 (en) 2003-06-18 2005-01-27 Smithkline Beecham Corporation Chemical compounds
US7157434B2 (en) 2003-10-27 2007-01-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
BRPI0617150A2 (pt) * 2005-10-06 2011-07-12 Schering Corp pirazolopirimidinas como inibidores de protéina cinase
CN101356171A (zh) 2005-11-15 2009-01-28 阿雷生物药品公司 作为erbbi型受体酪氨酸激酶抑制剂用于治疗增殖性疾病的n4-苯基-喹唑啉-4-胺衍生物和相关化合物
JP5156644B2 (ja) * 2006-01-25 2013-03-06 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー 不飽和ｍＴＯＲ阻害剤
CN101848909A (zh) 2006-02-14 2010-09-29 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡咯并[3,2-c]吡啶
EP2007373A4 (en) 2006-03-29 2012-12-19 Foldrx Pharmaceuticals Inc INHIBITION OF ALPHA SYNUCLEINE TOXICITY
EP1939197A1 (en) 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
BRPI0810086B1 (pt) * 2007-03-28 2021-11-09 Pharmacyclics Llc Composto inibidor de tirosina quinase de bruton, uso do referido composto e composição farmacêutica
BRPI0914233A2 (pt) 2008-06-19 2015-11-03 Astrazeneca Ab composto, uso de um composto, métodos para produzir um efeito inibidor de fgfr e para produzir um efeito anticâncer em um animal de sangue quente, composição farmacêutica, e, método para tratar uma doença
GB0819105D0 (en) * 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
JP2012525367A (ja) 2009-04-30 2012-10-22 ノバルティス アーゲー イミダゾール誘導体およびサイクリン依存性キナーゼ類のモジュレーターとしてのその使用
KR101483215B1 (ko) * 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
US9140689B2 (en) 2010-03-14 2015-09-22 Translational Genomics Research Institute Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
DE102011015188A1 (de) 2010-03-29 2011-09-29 Herbert Kannegiesser Gmbh Verfahren zur Nassbehandlung, insbesondere zum Reinigen, von Gegenständen
NZ702485A (en) * 2010-06-03 2016-04-29 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
BR112013025732B1 (pt) 2011-04-06 2022-02-22 Taiho Pharmaceutical Co., Ltd Compostos de imizazo-oxazina, seus usos e composição farmacêutica e fármaco compreendendo os mesmos
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
ES2516392T3 (es) 2012-01-19 2014-10-30 Taiho Pharmaceutical Co., Ltd. Compuesto de alquinilbenceno 3,5-disustituido y sal del mismo
CA2865021C (en) 2012-02-23 2020-06-30 Bayer Intellectual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
DK2868660T3 (da) 2012-07-02 2018-01-29 Taiho Pharmaceutical Co Ltd Anti-tumoreffekt-potentiator omfattende en imidazooxazin-forbindelse
EP2692740A1 (en) 2012-07-30 2014-02-05 Le Centre National De La Recherche Scientifique Glycan compositions, processes for preparing the same and their uses as a drug
CN103570725B (zh) 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
WO2014138364A2 (en) 2013-03-06 2014-09-12 Genentech, Inc. Methods of treating and preventing cancer drug resistance
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
EP3012327B1 (en) 2013-06-20 2020-12-16 Taiho Pharmaceutical Co., Ltd. METHOD FOR PREDICTING THERAPEUTIC EFFICACY OF PI3K/AKT/mTOR INHIBITOR ON BASIS OF PHLDA1 OR PIK3C2B EXPRESSION
DK3023100T3 (da) 2013-07-18 2019-05-27 Taiho Pharmaceutical Co Ltd Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer
US10124003B2 (en) 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
EP3135287B1 (en) 2014-04-25 2024-11-20 Chugai Seiyaku Kabushiki Kaisha Preparation containing tetracyclic compound at high dose
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
CN105859721B (zh) 2015-01-22 2018-04-17 浙江京新药业股份有限公司 一种伊布鲁替尼的制备方法
EP3263573B1 (en) 2015-02-27 2019-12-04 Taiho Pharmaceutical Co., Ltd. Crystal of imidazo-oxazine, pharmaceutical composition containing said crystal, and method for producing said crystal
ES2812785T3 (es) 2015-03-31 2021-03-18 Taiho Pharmaceutical Co Ltd Cristal de compuesto de alquinilo de benceno 3,5-disustituido
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CA3244408A1 (en) 2015-06-29 2025-06-13 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
KR20250007056A (ko) 2016-03-04 2025-01-13 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물

Also Published As

Publication number Publication date
EP3023100B1 (en) 2019-03-13
PL3023100T3 (pl) 2019-07-31
KR101974254B1 (ko) 2019-04-30
DK3023100T3 (da) 2019-05-27
KR20160032186A (ko) 2016-03-23
EP3023100A4 (en) 2017-01-04
WO2015008839A1 (ja) 2015-01-22
RU2016105133A3 (tr) 2018-02-28
TWI574691B (zh) 2017-03-21
PT3023100T (pt) 2019-05-29
ES2724929T3 (es) 2019-09-17
JPWO2015008839A1 (ja) 2017-03-02
HUE044273T2 (hu) 2019-10-28
RU2016105133A (ru) 2017-08-23
TW201536294A (zh) 2015-10-01
US20190183897A1 (en) 2019-06-20
US10894048B2 (en) 2021-01-19
US20160193210A1 (en) 2016-07-07
EP3023100A1 (en) 2016-05-25
JP6084291B2 (ja) 2017-02-22
RU2664118C2 (ru) 2018-08-15
AU2014291161B2 (en) 2018-04-26
AU2014291161A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
TR201907147T4 (tr) Fgfr inhibitörünün aralıklı uygulanmasına yönelik anti-tümör ilaç.
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
CY1122648T1 (el) Διαδικασια για την παρασκευη συνθεσεων που περιεχουν υαλουρονικο οξυ και υδροχλωρικη μεπιβακαϊνη
CY1125247T1 (el) Μεθοδοι θεραπειας καταθλιψης χρησιμοποιωντας ανταγωνιστες υποδοχεα ορεξινης-2
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
MX2015017532A (es) Métodos para modular la actividad del regulador de transmembrana de fibrosis quística.
MX389250B (es) Compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) y el uso de los mismos
UA116395C2 (uk) ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ
PH12016500356A1 (en) Nsaid and sigma receptor ligand combinations
TR201904327T4 (tr) Dimetilbenzoik asit bileşikleri.
TR201819576T4 (tr) Düşük Dozda İrinotekan Hidroklorid Hidrat İçeren Antitümör Ajanı
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
PH12016502130A1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
PH12015502282A1 (en) Alpha-2 adrenoceptor and sigma receptor ligand combinations
EA201591649A1 (ru) Составы с органическими соединениями
EA201692270A1 (ru) Производные нафтиридиндиона
EA201590250A1 (ru) Производные карбамат/мочевины
MX2015012318A (es) Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf.
EA201690818A1 (ru) Замещенные пиримидиновые соединения и их применение в качестве syk ингибиторов
EA201690236A1 (ru) Производные индол-3-карбинола
CY1121708T1 (el) Ενωσεις ουριας ινδανυλιου που αναστελλουν την ρ38 map kιναση
CY1120984T1 (el) Φαρμακευτικος συνδυασμος που περιεχει εναν αναστολεα κινασης φωσφατιδυλινοσιτολης-3 και εναν αναστολεα αρωματασης
EA201690593A1 (ru) Новые соединения мочевины
CY1120341T1 (el) Ενωση βενζοθειοφαινιου